DK2107906T3 - Hidtil ukendt terapeutisk anvendelse til behandling af leukæmier - Google Patents

Hidtil ukendt terapeutisk anvendelse til behandling af leukæmier

Info

Publication number
DK2107906T3
DK2107906T3 DK07872446.5T DK07872446T DK2107906T3 DK 2107906 T3 DK2107906 T3 DK 2107906T3 DK 07872446 T DK07872446 T DK 07872446T DK 2107906 T3 DK2107906 T3 DK 2107906T3
Authority
DK
Denmark
Prior art keywords
leukemias
treatment
therapeutic use
hitherto unknown
unknown therapeutic
Prior art date
Application number
DK07872446.5T
Other languages
English (en)
Inventor
Bernard Bourrie
Pierre Casellas
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38268928&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2107906(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Application granted granted Critical
Publication of DK2107906T3 publication Critical patent/DK2107906T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DK07872446.5T 2006-12-28 2007-12-27 Hidtil ukendt terapeutisk anvendelse til behandling af leukæmier DK2107906T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0611492A FR2910813B1 (fr) 2006-12-28 2006-12-28 Nouvelle utilisation therapeutique pour le traitement des leucemies
PCT/FR2007/002171 WO2008102075A2 (fr) 2006-12-28 2007-12-27 Nouvelle utilisation therapeutique pour le traitement des leucemies

Publications (1)

Publication Number Publication Date
DK2107906T3 true DK2107906T3 (da) 2012-03-19

Family

ID=38268928

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07872446.5T DK2107906T3 (da) 2006-12-28 2007-12-27 Hidtil ukendt terapeutisk anvendelse til behandling af leukæmier

Country Status (40)

Country Link
US (1) US8236811B2 (da)
EP (1) EP2107906B1 (da)
JP (1) JP5317987B2 (da)
KR (1) KR101458233B1 (da)
CN (1) CN101568338B (da)
AR (1) AR064550A1 (da)
AT (1) ATE534392T1 (da)
AU (1) AU2007347370B2 (da)
BR (1) BRPI0720963A2 (da)
CA (1) CA2672716C (da)
CL (1) CL2007003846A1 (da)
CO (1) CO6190610A2 (da)
CR (1) CR10881A (da)
CY (1) CY1112443T1 (da)
DK (1) DK2107906T3 (da)
EA (1) EA016873B1 (da)
EC (1) ECSP099449A (da)
ES (1) ES2377843T3 (da)
FR (1) FR2910813B1 (da)
GT (1) GT200900168A (da)
HK (1) HK1138189A1 (da)
HR (1) HRP20120170T1 (da)
JO (1) JO2748B1 (da)
MA (1) MA31100B1 (da)
MX (1) MX2009007054A (da)
MY (1) MY148515A (da)
NI (1) NI200900129A (da)
NO (1) NO20092496L (da)
NZ (1) NZ577991A (da)
PE (1) PE20081548A1 (da)
PL (1) PL2107906T3 (da)
PT (1) PT2107906E (da)
RS (1) RS52162B (da)
SI (1) SI2107906T1 (da)
SV (1) SV2009003315A (da)
TN (1) TN2009000234A1 (da)
TW (1) TWI433678B (da)
UA (1) UA97505C2 (da)
WO (1) WO2008102075A2 (da)
ZA (1) ZA200904478B (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2948568B1 (fr) * 2009-07-30 2012-08-24 Sanofi Aventis Formulation pharmaceutique
EP2638911A1 (en) 2012-03-14 2013-09-18 Sanofi Novel combinations for treating acute myeloid leukaemia or chronic myeloid leukaemia
EP3597179B1 (en) * 2013-12-13 2024-04-03 Novartis AG Pharmaceutical dosage forms
WO2021061874A2 (en) * 2019-09-23 2021-04-01 President And Fellows Of Harvard College Methods and compositions for treating acute myeloid leukemia

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1171218A (en) 1967-11-09 1969-11-19 Parke Davis & Co New Heterocyclic Amine Compounds and Methods for their Production
GEP20012444B (en) 1994-11-14 2001-05-25 Warner Lambert Company Us 6-Aryl Pyrido[2,3-d]Pyrimidines and Naphthyridines, Pharmaceutical Composition on Their Basis and Application for Inhibiting Cellular Proliferation
IL115256A0 (en) 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
US5620981A (en) 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
WO2001021577A2 (en) 1999-09-20 2001-03-29 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonist
JP4047010B2 (ja) * 2000-01-25 2008-02-13 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー ピリド〔２，３−ｄ〕ピリミジン−２，７−ジアミンキナーゼ阻害剤
CA2401368A1 (en) 2000-03-06 2001-09-27 Warner-Lambert Company 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors
CA2417942C (en) 2000-08-04 2010-06-29 Warner-Lambert Company 2-(4-pyridyl)amino-6-dialkoxyphenyl-pyrido[2,3-d]pyrimidin-7-ones
WO2003000011A2 (en) * 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel pyridopyrimidines and uses thereof
US20050009849A1 (en) 2003-01-03 2005-01-13 Veach Darren R. Pyridopyrimidine kinase inhibitors
TW200502236A (en) 2003-03-28 2005-01-16 Hoffmann La Roche Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
WO2005105097A2 (en) 2004-04-28 2005-11-10 Gpc Biotech Ag Pyridopyrimidines for treating inflammatory and other diseases
FR2873118B1 (fr) * 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
UY29017A1 (es) 2004-07-16 2006-02-24 Boehringer Ingelheim Int Inhibidores de polimerasa viral
FR2887882B1 (fr) * 2005-07-01 2007-09-07 Sanofi Aventis Sa Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
FR2896246B1 (fr) 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.

Also Published As

Publication number Publication date
CN101568338A (zh) 2009-10-28
CA2672716A1 (fr) 2008-08-28
HRP20120170T1 (hr) 2012-03-31
KR20090103899A (ko) 2009-10-01
JP5317987B2 (ja) 2013-10-16
CN101568338B (zh) 2011-11-23
ZA200904478B (en) 2010-08-25
AU2007347370A1 (en) 2008-08-28
JO2748B1 (en) 2014-03-15
NO20092496L (no) 2009-07-23
ATE534392T1 (de) 2011-12-15
NI200900129A (es) 2011-12-13
ES2377843T3 (es) 2012-04-02
FR2910813B1 (fr) 2009-02-06
SI2107906T1 (sl) 2012-03-30
CL2007003846A1 (es) 2009-01-23
AR064550A1 (es) 2009-04-08
TW200833343A (en) 2008-08-16
KR101458233B1 (ko) 2014-11-04
US8236811B2 (en) 2012-08-07
SV2009003315A (es) 2010-02-05
AU2007347370B2 (en) 2013-05-23
WO2008102075A3 (fr) 2008-12-11
EA200970639A1 (ru) 2010-04-30
RS52162B (en) 2012-08-31
ECSP099449A (es) 2009-07-31
NZ577991A (en) 2012-01-12
MY148515A (en) 2013-04-30
TWI433678B (zh) 2014-04-11
CY1112443T1 (el) 2015-12-09
JP2010514743A (ja) 2010-05-06
FR2910813A1 (fr) 2008-07-04
CR10881A (es) 2009-08-12
EP2107906A2 (fr) 2009-10-14
MA31100B1 (fr) 2010-01-04
PL2107906T3 (pl) 2012-04-30
UA97505C2 (ru) 2012-02-27
PE20081548A1 (es) 2009-01-04
GT200900168A (es) 2010-03-19
TN2009000234A1 (fr) 2010-10-18
CO6190610A2 (es) 2010-08-19
WO2008102075A2 (fr) 2008-08-28
EA016873B1 (ru) 2012-08-30
CA2672716C (fr) 2013-05-28
MX2009007054A (es) 2009-08-12
EP2107906B1 (fr) 2011-11-23
HK1138189A1 (en) 2010-08-20
PT2107906E (pt) 2012-03-05
US20090298790A1 (en) 2009-12-03
BRPI0720963A2 (pt) 2014-03-18

Similar Documents

Publication Publication Date Title
CY2020043I2 (el) Παγιδες gdf για χρηση στη θεραπευτικη αντιμετωπιση της αναιμιας
LTPA2018006I1 (lt) Pakeistųjų oksazolidinonų kombinuota terapija
DK2211846T3 (da) Hidtil ukendte tilgange til behandling af CMT- og beslÇgtede lidelser
DK1928438T3 (da) Anvendelse af ibudilast til behandling af stofafhængighed
DK3403657T3 (da) Anvendelse af oligouronater til behandling af slimhyperviskositet
DK1885380T3 (da) Natriummetaarsenit til anvendelse til behandling af metastatiske neoplastiske sygdomme
DK2100614T3 (da) Antistof mod PDGFR-alfa til anvendelse ved behandlingen af tumorer
DK1863899T3 (da) Hudbehandlingspræparater
NO20070251A (no) Brønnbehandling
DK2101805T3 (da) Integrinligander til anvendelse i behandling af cancer
NO20070297A (no) Brønnbehandling
BRPI0906167A2 (pt) uso de inibidor de serina protease no tratamento de doenças de pele.
DK2235002T3 (da) 4-pyridinonforbindelser og anvendelse heraf til behandling af cancer
DK2144905T3 (da) Terapeutiske midler
DK2035369T3 (da) Terapeutiske
DK2200600T3 (da) Neramexan til anvendelse ved behandlingen af subakut tinnitus
DK1918252T3 (da) Vandbehandlingskartouche
DK2173831T3 (da) Brøndbehandling
DK3211005T3 (da) Terapeutisk anvendelse af specifik ligand i msrv-associerede sygdomme
DK3326681T3 (da) Indretning til behandling af analsphincteren
DK2117565T3 (da) Anvendelse af chitosaner til behandlingen af negleinflammatoriske sygdomme
DK2310042T3 (da) Anvendelse af pasireotid til behandling af endogen hyperinsulinæmisk hypoglykæmi
BRPI0822129A2 (pt) Inibidores de aldh-2c no tratamento de vício.
DK2323644T3 (da) N-substituerede benzenpropanamid- eller benzenpropenamidderivater til anvendelse ved behandlingen af smerte
DK1933840T3 (da) Anvendelse af delmopinol i behandlingen af acne